A study reported by US researchers says certain weight-loss injections used to treat diabetes are associated with a higher risk of hair loss compared with other diabetes medications. The articles say the commonly used injections are linked to a 70% higher risk of developing baldness than an alternative class of diabetes treatments. The reporting also notes that the risk appears to be worse for women.
The coverage points to earlier findings and frames them in the context of how widely the drugs are used. One report states that the injections are used by about 1.6 million people in the UK.
Both outlets describe the same core claim: the study compares outcomes for people taking different diabetes therapies and finds a relative increase in baldness associated with specific injections. The reports do not provide further clinical detail on mechanisms, severity, or how the study defines or measures hair loss, nor do they discuss whether the findings change prescribing guidance. The articles present the results as observational evidence of risk differences rather than proof of causation.
